Sugi Predict

Sugi Predict / Compounds / SCHEMBL2459549

SCHEMBL2459549

SCHEMBL2459549

Cc1ccc(S(=O)(=O)OCC2CC(C3=C4C=NC=C[N+]4(N)C(c4cccc(OCc5ccccc5)c4)=N3)C2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 8/20 0.37
▸ TNK2 Q07912 1/20 0.37
▸ MMP1 P03956 1/20 0.34
▸ MMP2 P08253 1/20 0.34
▸ MMP7 P09237 1/20 0.34
▸ MMP9 P14780 1/20 0.34
▸ MMP12 P39900 1/20 0.34
▸ MMP14 P50281 1/20 0.34
▸ MMP15 P51511 1/20 0.34
▸ MMP16 P51512 1/20 0.34
▸ MMP26 Q9NRE1 1/20 0.34
▸ PTGS2 P35354 1/20 0.33
▸ LDHA P00338 1/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ ROCK2 O75116 2/20 0.33
▸ PRKD3 O94806 2/20 0.33
▸ INSR P06213 2/20 0.33
▸ LYN P07948 2/20 0.33
▸ RET P07949 2/20 0.33
▸ FGFR1 P11362 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL399874 0.94 IGF1R (0.35) IGF1RTNK2MMP1MMP2MMP7
SCHEMBL2460823 0.86 MMP1 (0.35) IGF1RTNK2MMP1MMP2MMP7
SCHEMBL1128928 0.86 HTT (0.35) TNK2
SCHEMBL2460659 0.85 IGF1R (0.47) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL398879 0.83 IGF1R (0.33) IGF1RINSRKDR
SCHEMBL2459711 0.83 IGF1R (0.41) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2460547 0.82 IGF1R (0.48) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2458683 0.82 IGF1R (0.37) IGF1RTNK2MAOBBRD4PLAT
SCHEMBL2457535 0.81 IGF1R (0.38) IGF1RTNK2MAOBBRD4
SCHEMBL2460636 0.81 IGF1R (0.39) IGF1RTNK2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885MMP1 1460/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885MMP1 1460/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885MMP1 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.